- Investing.com
RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States and internationally. The company operates in two segments, Imaging Centers and Digital Health. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as solutions for prostate cancer screening. In addition, it develops and delivers AI-powered health informatics solutions to drive quality, efficiency, and outcomes in imaging and radiology; informatics designed for outpatient radiology; and DeepHealth OS, a cloud-native operating system that helps in the operations of the radiology service. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.
Imaging Innovation | RadNet's DeepHealth segment offers advanced imaging products with superior speed and integration, positioning the company as a leader in diagnostic technology |
Strategic Expansion | Explore RadNet's recent acquisition of iCAD for $103 million, aimed at accelerating growth and enhancing its product offerings in the competitive healthcare market |
Financial Resilience | Despite industry challenges, RadNet outperformed revenue expectations in Q1 2025, with analysts projecting a return to profitability and EPS growth in upcoming fiscal years |
Market Outlook | Analysts express increased confidence in RadNet's prospects, with price targets ranging from $60 to $80 per share, reflecting optimism about the company's future growth potential |
Metrics to compare | RDNT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRDNTPeersSector | |
---|---|---|---|---|
P/E Ratio | −361.4x | −0.1x | −0.6x | |
PEG Ratio | 1.48 | 0.01 | 0.00 | |
Price/Book | 5.8x | 1.3x | 2.6x | |
Price / LTM Sales | 2.8x | 1.1x | 3.3x | |
Upside (Analyst Target) | 7.0% | 35.2% | 37.4% | |
Fair Value Upside | Unlock | 7.7% | 4.5% | Unlock |